These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32400907)

  • 1. Alternatives to immediate release tacrolimus in solid organ transplant recipients: When the gold standard is in short supply.
    Jorgenson MR; Descourouez JL; Brady BL; Bowman L; Hammad S; Kaiser TE; Laub MR; Melaragno JI; Park JM; Chandran MM
    Clin Transplant; 2020 Jul; 34(7):e13903. PubMed ID: 32400907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LCP-Tacrolimus Extended-Release (Envarsus XR) Use in Adolescent and Young Adult Solid Organ Transplant Recipients.
    Bae EK; Chandran MM; Everitt MD; Benz E; Bock M
    Clin Transplant; 2024 Aug; 38(8):e15417. PubMed ID: 39087462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies.
    Vadcharavivad S; Saengram W; Phupradit A; Poolsup N; Chancharoenthana W
    Drugs; 2019 Dec; 79(18):1947-1962. PubMed ID: 31713065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial.
    Suwelack B; Bunnapradist S; Meier-Kriesche U; Stevens DR; Procaccianti C; Morganti R; Budde K
    Ann Transplant; 2020 Jul; 25():e923278. PubMed ID: 32719307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in kidney transplant recipients treated with immediate-release tacrolimus capsules versus extended-release tacrolimus capsules: A cohort study.
    Ha YP; Divard G; Mitra N; Putt ME; Pallet N; Loupy A; Anglicheau D; Trofe-Clark J; Legendre C; Bloom RD; Reese PP
    Clin Transplant; 2023 Jan; 37(1):e14840. PubMed ID: 36374204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial.
    Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S
    Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP-Tacrolimus.
    Taber DJ; Bartlett F; Patel N; Sprague T; Patel S; Newman J; Andrade E; Rao N; Salas MAP; Casey M; Dubay D; Rohan V
    Clin Transplant; 2023 May; 37(5):e14941. PubMed ID: 36809653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis.
    Saengram W; Vadcharavivad S; Poolsup N; Chancharoenthana W
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1249-1260. PubMed ID: 29961086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus trough levels higher than 6 ng/mL might not be required after a year in stable kidney transplant recipients.
    Jung HY; Seo MY; Jeon Y; Huh KH; Park JB; Jung CW; Lee S; Han SY; Ro H; Yang J; Ahn C; Choi JY; Cho JH; Park SH; Kim YL; Kim CD
    PLoS One; 2020; 15(7):e0235418. PubMed ID: 32614859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial.
    Plischke M; Riegersperger M; Dunkler D; Heinze G; Kikić Ž; Winkelmayer WC; Sunder-Plassmann G
    PLoS One; 2015; 10(8):e0135674. PubMed ID: 26270340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
    PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.